• 575 Citations
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Training Experience

2009Residency, Rush University Medical Center
2012Fellowship, Rush University Medical Center

Education/Academic qualification

MS, Rush University

… → 2012

MD, University of Western Ontario

… → 2006

Fingerprint Dive into the research topics where Reem Karmali is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 20 Similar Profiles
Lymphoma Medicine & Life Sciences
Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences
Cell Transplantation Medicine & Life Sciences
Survival Medicine & Life Sciences
Follicular Lymphoma Medicine & Life Sciences
B-Cell Lymphoma Medicine & Life Sciences
Mantle-Cell Lymphoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2013 2024

Research Output 2008 2019

  • 575 Citations
  • 29 Article
  • 4 Review article
  • 1 Chapter

Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin

Badar, T., Hamadani, M., Bachanova, V., Maddocks, K. J., Umyarova, E., Chavez, J. C., Epperla, N., Chhabra, S., Xavier, A. C., Karmali, R., Salhab, M., Reddy, N., Glenn, M. J., Hernandez-Ilizaliturri, F. J., Flowers, C. R., Evens, A. M., Zhou, Z., Lansigan, F., Barta, S. K., Cohen, J. B. & 2 others, Fenske, T. S. & Costa, L. J., Mar 21 2019, In : Leukemia and Lymphoma. 60, 4, p. 940-946 7 p.

Research output: Contribution to journalArticle

Lymphoma, Large B-Cell, Diffuse
Treatment Failure
Drug Therapy

Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma

Burkart, M., Schieber, M., Basu, S., Shah, P., Venugopal, P., Borgia, J. A., Gordon, L. I. & Karmali, R., Jul 1 2019, In : British Journal of Haematology. 186, 1, p. 45-53 9 p.

Research output: Contribution to journalArticle

Insulin-Like Growth Factor Binding Protein 6

Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2

Godfrey, J. K., Nabhan, C., Karrison, T., Kline, J. P., Cohen, K. S., Bishop, M. R., Stadler, W. M., Karmali, R., Venugopal, P., Rapoport, A. P. & Smith, S. M., Jun 1 2019, In : Cancer. 125, 11, p. 1830-1836 7 p.

Research output: Contribution to journalArticle

B-Cell Lymphoma
Maximum Tolerated Dose

Revving up the immune engine in cHL

Karmali, R. & Gordon, L. I., Jul 4 2019, In : Blood. 134, 1, p. 1-2 2 p.

Research output: Contribution to journalReview article

Stem Cell Transplantation
Cell death
Stem cells
Hodgkin Disease

Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status

Behdad, A., Boddy, C. S., Fought, A. J., Taxter, T., Falkiewicz, M. K., Ayers, E., Chen, Q. C., Chen, Y-H., Karmali, R., Pro, B., Winter, J. N., Landsburg, D. J., Gordon, L. I. & Kaplan, J. B., Jan 1 2019, In : Leukemia and Lymphoma.

Research output: Contribution to journalArticle

Follicular Lymphoma
Lymphoma, Large B-Cell, Diffuse
Disease-Free Survival